SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-009079
Filing Date
2021-05-05
Accepted
2021-05-05 16:03:40
Documents
15
Period of Report
2021-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeri-20210505.htm   iXBRL 8-K 44708
2 EX-99.1 aeri-1q21ex991earningsrele.htm EX-99.1 158475
  Complete submission text file 0001628280-21-009079.txt   363244

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aeri-20210505.xsd EX-101.SCH 2445
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aeri-20210505_cal.xml EX-101.CAL 728
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aeri-20210505_def.xml EX-101.DEF 1665
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aeri-20210505_lab.xml EX-101.LAB 24270
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aeri-20210505_pre.xml EX-101.PRE 12664
8 EXTRACTED XBRL INSTANCE DOCUMENT aeri-20210505_htm.xml XML 11639
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 21893144
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences